BridgeBio

Performance

About BridgeBio

BridgeBio is a biopharmaceutical company focused on designing transformative medicines for patients with genetic diseases and cancers driven by clear genetic drivers. It develops and advances therapies across its pipeline, including products like Attruby (acoramidis) and Nulibry (fosdenopterin), aiming to bring clinically meaningful cures to patients. The company emphasizes a platform that accelerates discovery and development, combining science and finance to support patients and partners. Headquartered in Palo Alto, California, BridgeBio engages in research, collaborations, and patient-focused initiatives to address rare genetic diseases and oncology indications.